# Amplimmune

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/amplimmune

- Industry: Biotechnology
- Headquarters: Rockville, US
- Website: www.amplimmune.com
- Total disclosed funding: $5.9M
- Latest round: Series A (Mar 31, 2007)
- Investors on record: 2

## About

Amplimmune, Inc. is a biotech company dedicated to advancing therapeutics targeting immune modulation for the treatment of cancer and other serious diseases through innovative research and development.Amplimmune, Inc. focuses on the development of immune-modulating therapies. Established in Rockville, US, the company was acquired by MedImmune, Inc. in August 2013 for an initial USD 225 million, with potential deferred payments of up to USD 275 million based on development milestones. The company has engaged in 2 significant deals since its inception, with the most recent deal completed in 2013.Amplimmune, Inc. specializes in creating biological products that harness the immune system to combat diseases such as cancer. The company’s pipeline includes various therapeutics designed to improve immune responses, potentially leading to better outcomes in oncology and other therapeutic areas, benefiting healthcare providers and patients globally.Amplimmune, Inc.'s total fundraising to date amounts to USD 5.88 mn. The company's revenue generation strategies are likely focused on advancing their product pipeline and securing partnership agreements with research institutions and pharmaceutical companies to enhance market access and distribution of their therapeutics.Looking ahead, Amplimmune, Inc. aims to leverage its recent funding from the Add-on round to support the ongoing development of its therapeutic products, with expectations of entering new markets by 2015. The planned expansion includes targeting key regions in North America and Europe. The anticipated growth will also focus on achieving predefined development targets that could unlock additional funding, thereby accelerating the pace of innovation and market introduction.

## Funding rounds

- Series A, Mar 31, 2007, $5.9M — InterWest Partners, Wellcome Trust

## Investors

- InterWest Partners (https://capitalatlas.ai/funds/interwest-partners) — Series A
- Wellcome Trust — Series A